VIRX
Viracta Therapeutics, Inc.
Price Chart
No historical data available
Latest Quote
$0.01
+0.00 (+0.00%)
Current Price
| Previous Close | $0.01 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 379,813 |
Stock Information
| Shares Outstanding | 39.74M |
| Total Debt | $16.91M |
| Cash Equivalents | $21.13M |
| Net Income | $-43.29M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $389K |
| EPS (TTM) | $-1.10 |
| Exchange | PNK |
Recent Price History
No history data available. Data will be fetched automatically.
About Viracta Therapeutics, Inc.
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Period:
Loading...
Income Statement (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Interest Expense | $3,704,000 | $577,000 | $491,000 |
| Total Expenses | $50,693,000 | $50,589,000 | $25,798,000 |
| Other Income Expense | $-6,000 | $798,000 | $-88,511,000 |
| Other Non Operating Income Expenses | $-6,000 | $798,000 | $-290,000 |
| Net Non Operating Interest Income Expense | $-359,000 | $594,000 | $-453,000 |
| Interest Expense Non Operating | $3,704,000 | $577,000 | $491,000 |
| Operating Expense | $50,693,000 | $50,589,000 | $25,798,000 |
| General And Administrative Expense | $17,324,000 | $24,327,000 | $15,437,000 |
| Other Operating Expenses | - | - | $-13,500,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Net Interest Income | $-359,000 | $594,000 | $-453,000 |
| Interest Income | $3,345,000 | $1,171,000 | $38,000 |
| Normalized Income | $-51,058,000 | $-49,197,000 | $-26,541,000 |
| Net Income From Continuing And Discontinued Operation | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Total Operating Income As Reported | $-50,693,000 | $-50,589,000 | $-114,276,000 |
| Net Income Common Stockholders | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Net Income | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Net Income Including Noncontrolling Interests | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Net Income Continuous Operations | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Pretax Income | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Interest Income Non Operating | $3,345,000 | $1,171,000 | $38,000 |
| Operating Income | $-50,693,000 | $-50,589,000 | $-25,798,000 |
| Special Income Charges | - | $0 | $-88,221,000 |
| Per Share | |||
| Diluted EPS | $-1.32 | $-1.30 | $-3.60 |
| Basic EPS | $-1.32 | $-1.30 | $-3.60 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-46,862,000 | $-48,410,000 | $-25,872,000 |
| Reconciled Depreciation | $492,000 | $210,000 | $178,000 |
| EBITDA (Bullshit earnings) | $-46,862,000 | $-48,410,000 | $-114,093,000 |
| EBIT | $-47,354,000 | $-48,620,000 | $-114,271,000 |
| Diluted Average Shares | $38,624,462 | $37,790,981 | $31,870,067 |
| Basic Average Shares | $38,624,462 | $37,790,981 | $31,870,067 |
| Diluted NI Availto Com Stockholders | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Research And Development | $33,369,000 | $26,262,000 | $23,861,000 |
| Selling General And Administration | $17,324,000 | $24,327,000 | $15,437,000 |
| Other Gand A | $17,324,000 | $24,327,000 | $15,437,000 |
| Total Unusual Items | - | $0 | $-88,221,000 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-88,221,000 |
| Other Special Charges | - | - | $88,221,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $18,319,000 | $61,103,000 | $94,371,000 |
| Total Assets | $56,692,000 | $95,991,000 | $108,552,000 |
| Total Non Current Assets | $1,728,000 | $2,244,000 | $3,279,000 |
| Other Non Current Assets | $1,264,000 | $1,830,000 | $2,397,000 |
| Current Assets | $54,964,000 | $93,747,000 | $105,273,000 |
| Prepaid Assets | $992,000 | $1,794,000 | $1,719,000 |
| Receivables | $281,000 | $910,000 | - |
| Other Receivables | $168,000 | $798,000 | - |
| Accrued Interest Receivable | $113,000 | $112,000 | - |
| Cash Cash Equivalents And Short Term Investments | $53,691,000 | $91,043,000 | $103,554,000 |
| Cash And Cash Equivalents | $12,317,000 | $36,773,000 | $103,554,000 |
| Other Current Assets | - | $2,704,000 | $1,719,000 |
| Debt | |||
| Net Debt | $12,957,000 | - | - |
| Total Debt | $25,556,000 | $25,155,000 | $5,478,000 |
| Current Debt And Capital Lease Obligation | $25,556,000 | $278,000 | $381,000 |
| Current Debt | $25,274,000 | - | - |
| Other Current Borrowings | $25,274,000 | - | - |
| Long Term Debt And Capital Lease Obligation | - | $24,877,000 | $5,097,000 |
| Long Term Debt | - | $24,877,000 | $4,819,000 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $38,373,000 | $34,888,000 | $14,181,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $24,877,000 | $5,097,000 |
| Current Liabilities | $38,373,000 | $10,011,000 | $9,084,000 |
| Payables And Accrued Expenses | $12,817,000 | $9,733,000 | $8,703,000 |
| Payables | $2,441,000 | $2,540,000 | $2,901,000 |
| Accounts Payable | $2,441,000 | $2,540,000 | $2,901,000 |
| Derivative Product Liabilities | - | - | $0 |
| Equity | |||
| Common Stock Equity | $12,867,000 | $55,651,000 | $88,919,000 |
| Preferred Stock Equity | $5,452,000 | $5,452,000 | $5,452,000 |
| Total Equity Gross Minority Interest | $18,319,000 | $61,103,000 | $94,371,000 |
| Stockholders Equity | $18,319,000 | $61,103,000 | $94,371,000 |
| Gains Losses Not Affecting Retained Earnings | $9,000 | $-178,000 | $0 |
| Other Equity Adjustments | $9,000 | $-178,000 | - |
| Retained Earnings | $-265,932,000 | $-214,874,000 | $-165,677,000 |
| Preferred Securities Outside Stock Equity | - | - | $0 |
| Other | |||
| Ordinary Shares Number | $39,093,509 | $38,345,140 | $37,424,863 |
| Share Issued | $39,093,509 | $38,345,140 | $37,424,863 |
| Tangible Book Value | $12,867,000 | $55,651,000 | $88,919,000 |
| Invested Capital | $38,141,000 | $80,528,000 | $93,738,000 |
| Working Capital | $16,591,000 | $83,736,000 | $96,189,000 |
| Capital Lease Obligations | $282,000 | $278,000 | $659,000 |
| Total Capitalization | $18,319,000 | $85,980,000 | $99,190,000 |
| Additional Paid In Capital | $278,786,000 | $270,699,000 | $254,592,000 |
| Capital Stock | $5,456,000 | $5,456,000 | $5,456,000 |
| Common Stock | $4,000 | $4,000 | $4,000 |
| Preferred Stock | $5,452,000 | $5,452,000 | $5,452,000 |
| Current Capital Lease Obligation | $282,000 | $278,000 | $381,000 |
| Current Accrued Expenses | $10,376,000 | $7,193,000 | $5,802,000 |
| Net PPE | $464,000 | $414,000 | $882,000 |
| Gross PPE | $464,000 | $414,000 | $882,000 |
| Other Properties | $464,000 | $414,000 | $882,000 |
| Other Short Term Investments | $41,374,000 | $54,270,000 | $0 |
| Long Term Capital Lease Obligation | - | $0 | $278,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-40,030,000 | $-35,502,000 | $-23,103,000 |
| Operating Activities | |||
| Operating Cash Flow | $-39,892,000 | $-35,457,000 | $-18,851,000 |
| Cash Flow From Continuing Operating Activities | $-39,892,000 | $-35,457,000 | $-18,851,000 |
| Operating Gains Losses | - | - | $290,000 |
| Investing Activities | |||
| Capital Expenditure | $-138,000 | $-45,000 | $-4,252,000 |
| Investing Cash Flow | $14,998,000 | $-53,866,000 | $12,891,000 |
| Cash Flow From Continuing Investing Activities | $14,998,000 | $-53,866,000 | $12,891,000 |
| Financing Activities | |||
| Issuance Of Capital Stock | $299,000 | $2,331,000 | $62,320,000 |
| Financing Cash Flow | $438,000 | $22,542,000 | $62,425,000 |
| Cash Flow From Continuing Financing Activities | $438,000 | $22,542,000 | $62,425,000 |
| Net Common Stock Issuance | $299,000 | $2,331,000 | $62,320,000 |
| Common Stock Issuance | $299,000 | $2,331,000 | $62,320,000 |
| Net Preferred Stock Issuance | - | - | $0 |
| Preferred Stock Issuance | - | - | $0 |
| Other | |||
| Issuance Of Debt | $0 | $19,986,000 | - |
| Interest Paid Supplemental Data | $3,070,000 | $454,000 | $343,000 |
| End Cash Position | $12,317,000 | $36,773,000 | $103,554,000 |
| Beginning Cash Position | $36,773,000 | $103,554,000 | $47,089,000 |
| Changes In Cash | $-24,456,000 | $-66,781,000 | $56,465,000 |
| Proceeds From Stock Option Exercised | $139,000 | $225,000 | $339,000 |
| Net Issuance Payments Of Debt | $0 | $19,986,000 | $-234,000 |
| Net Long Term Debt Issuance | $0 | $19,986,000 | $-234,000 |
| Long Term Debt Issuance | $0 | $19,986,000 | - |
| Net Investment Purchase And Sale | $15,136,000 | $-53,821,000 | $0 |
| Sale Of Investment | $82,272,000 | $16,799,000 | $0 |
| Purchase Of Investment | $-67,136,000 | $-70,620,000 | $0 |
| Net PPE Purchase And Sale | $-138,000 | $-45,000 | $-252,000 |
| Purchase Of PPE | $-138,000 | $-45,000 | $-252,000 |
| Change In Working Capital | $5,079,000 | $608,000 | $1,680,000 |
| Change In Other Current Liabilities | $-4,000 | $-7,000 | $12,000 |
| Change In Other Current Assets | $566,000 | $567,000 | $884,000 |
| Change In Payables And Accrued Expense | $3,086,000 | $1,033,000 | $1,829,000 |
| Change In Accrued Expense | $3,184,000 | $1,394,000 | $907,000 |
| Change In Payable | $-98,000 | $-361,000 | $922,000 |
| Change In Account Payable | $-98,000 | $-361,000 | $922,000 |
| Change In Prepaid Assets | $1,431,000 | $-985,000 | $-1,045,000 |
| Stock Based Compensation | $7,649,000 | $13,548,000 | $5,542,000 |
| Amortization Of Securities | $-2,054,000 | $-626,000 | $0 |
| Depreciation Amortization Depletion | $492,000 | $210,000 | $178,000 |
| Depreciation And Amortization | $492,000 | $210,000 | $178,000 |
| Net Income From Continuing Operations | $-51,058,000 | $-49,197,000 | $-114,762,000 |
| Net Business Purchase And Sale | - | $0 | $17,143,000 |
| Sale Of Business | - | $0 | $17,143,000 |
| Net Intangibles Purchase And Sale | - | $0 | $-4,000,000 |
| Purchase Of Intangibles | - | $0 | $-4,000,000 |
| Repayment Of Debt | - | - | $-234,000 |
| Long Term Debt Payments | - | - | $-234,000 |
| Other Non Cash Items | - | - | $88,221,000 |
| Gain Loss On Investment Securities | - | - | $290,000 |
Fetched: 2026-02-02